Posts by: Patricia Inacio

News

Rare variants in genes that regulate the end regions of chromosomes — called telomeres — are linked with worse survival rates after lung transplant in pulmonary fibrosis (PF) patients, ... Read more

April 10, 2019

High Levels of Vimentin Protein Linked to Lung Fibrosis, Study Shows

News

High levels of the protein vimentin in the lung tissue of patients with idiopathic pulmonary fibrosis (IPF) contribute to disease progression, an early study’s results show. Inhibiting vimentin can prevent fibroblasts — ... Read more

April 8, 2019

Secondary Insurance Coverage Boosts Adherence to Treatment with Ofev, Esbriet, Study Finds

Esbriet, News

Although patients with idiopathic pulmonary fibrosis (IPF) who take Ofev (nintedanib) or Esbriet (pirfenidone) have similar clinical outcomes, adherence to treatment is higher among those who have secondary insurance coverage, ... Read more

March 26, 2019April 4, 2019

Esbriet Safe and Effective for Patients with Advanced Idiopathic Pulmonary Fibrosis, Trial Suggests

Esbriet, News

A post-hoc analysis of the Phase 3 RECAP trial shows that long-term treatment with Esbriet (pirfenidone) is safe and similarly effective in patients with advanced idiopathic pulmonary fibrosis (IPF) as in ... Read more

March 25, 2019March 27, 2019

Protein that Drives Cancer Is Potential New Therapeutic Target for Idiopathic Pulmonary Fibrosis, Study Suggests

News

High levels of PD-L1 protein were found in the most aggressive fibroblasts that drive idiopathic pulmonary fibrosis (IPF) progression, making the protein — whose levels are increased in cancer ... Read more

March 12, 2019March 12, 2019

Ofev Affects Cell Cycle Genes in IPF Fibroblasts, Study Finds

News

Ofev (nintedanib) may exert its therapeutic benefits by halting the activity of genes that promote proliferation of fibroblasts in idiopathic pulmonary fibrosis (IPF), a next-generation sequencing study suggests. The ... Read more

February 18, 2019February 22, 2019

Protein Called TRAIL Linked to Lung Fibrosis by Igniting ‘Signaling Cascade,’ Study Reports

News

A protein in the tumor necrosis factor (TNF) alpha family, called TRAIL, regulates a signaling cascade that promotes pulmonary fibrosis, researchers report, suggesting this protein opens potential new avenues ... Read more

January 28, 2019January 28, 2019

Specific Protein Promotes Cell Interaction that Fuels Profibrotic Environment, Study Finds

News

A protein called cadherin-11 (CDH11) ties together macrophages and myofibroblasts in an “eternal hug” in the lungs of idiopathic pulmonary fibrosis (IPF) patients, promoting a profibrotic environment, a study ... Read more

January 23, 2019January 31, 2019

Real-world Use of Esbriet and Ofev Supports Their Safety and Tolerability, Study Says

Esbriet, News

The tolerability and safety of Ofev (nintedanib) and Esbriet (pirfenidone) treatments in a small group of patients with idiopathic pulmonary fibrosis (IPF) in South England were found to be ... Read more

January 11, 2019January 15, 2019

Sprycel/Quercetin Combo Therapy Improves Physical Function in IPF Patients, Phase 1 Trial Shows

News

A Phase 1 trial shows that combining Sprycel (dasatinib) with the plant-based flavonoid quercetin improved the physical function of people with idiopathic pulmonary fibrosis (IPF). However, patients’ pulmonary function ... Read more

Posts by: Patricia Inacio

Patricia Inacio

Rare Gene Variants Linked to Worse Lung Transplant Outcomes in PF Patients

High Levels of Vimentin Protein Linked to Lung Fibrosis, Study Shows

Secondary Insurance Coverage Boosts Adherence to Treatment with Ofev, Esbriet, Study Finds

Esbriet Safe and Effective for Patients with Advanced Idiopathic Pulmonary Fibrosis, Trial Suggests

Protein that Drives Cancer Is Potential New Therapeutic Target for Idiopathic Pulmonary Fibrosis, Study Suggests

Ofev Affects Cell Cycle Genes in IPF Fibroblasts, Study Finds

Protein Called TRAIL Linked to Lung Fibrosis by Igniting ‘Signaling Cascade,’ Study Reports

Specific Protein Promotes Cell Interaction that Fuels Profibrotic Environment, Study Finds

Real-world Use of Esbriet and Ofev Supports Their Safety and Tolerability, Study Says

Sprycel/Quercetin Combo Therapy Improves Physical Function in IPF Patients, Phase 1 Trial Shows

Pin It on Pinterest